CD95-Fc fusion proteins

Details CD95-Fc fusion proteins CD95-Fc fusion proteins

2011-08-30

2011-08-30

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C435S069700, C435S325000, C530S350000, C536S023400, C514S021200, C514S021300

Reexamination Certificate

active

08007813

ABSTRACT:
The invention relates to fusion proteins comprising at least a first domain and a second domain selected from a constant Fc immunoglobulin domain.

REFERENCES:
patent: 6015559 (2000-01-01), Lynch et al.
patent: 0 526 452 (1993-02-01), None
patent: 0 965 637 (1999-12-01), None
patent: 0 992 243 (2000-04-01), None
patent: WO 91/08298 (1991-06-01), None
patent: WO 95/27735 (1995-10-01), None
patent: WO 98/36768 (1998-08-01), None
patent: WO 99/50413 (1999-10-01), None
patent: WO 00/18932 (2000-04-01), None
patent: WO 01/41803 (2001-06-01), None
patent: WO 01/49866 (2001-07-01), None
patent: WO 01/49866 (2001-07-01), None
patent: WO 02/066514 (2002-08-01), None
patent: WO 02/079232 (2002-10-01), None
patent: WO 02/079415 (2002-10-01), None
patent: WO 02/090553 (2002-11-01), None
patent: WO 02/090553 (2002-11-01), None
Wells, J.A. (1990). Additivity of mutational effects in proteins. Biochemistry. 29(37):8509-8517.
Ngo et al. (1994). Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 491-495.
Palùet al. (1999). In pursuit of new developments for gene therapy. Journal of Biotechnology. 68:1-13.
Phillips, A.J. (2001). The challenge of gene therapy and DNA delivery. Journal of Pharmacy and Pharmacology. 53:1169-1174.
Wang et al. (1999). Rapid analysis of gene expression (RAGE) facilitates universal expression profiling. Nucleic Acds Research. 27(23):4609-4618.
Kaufman et al. (1999). Transgenic analysis of a 100-kb human B-globulin cluster-containing DNA fragment propagated as a bacterial artificial chromosome. Blood. 94(9):3178-3184.
Demjen, D et al., “Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury”,Nat. Med10(4):389-395, 2004.
Kim, Yon Su et al., “Targeting the IL-15 Receptor with an Antagonist IL-15 Mutant/Fc 2a Protein Blocks Delayed-Type Hypersensitivity”,J Immunol160:5742-5748, 1998.
Martin-Villalba, A. et al., “Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke”,Cell Death Differ. 8(7):679-686, 2001.
Smith, CA et al., “CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family cytokines with homology to TNF”,Cell73(7):1349-1360, 1993.
Capon, Daniel J. et al., “Designing CD4 immunoadhesins for AIDS therapy”, Nature, vol. 337, Feb. 9, 1989, pp. 525-531.
Haak-Frendscho, M. et al., “Inhibition of interferon-y by an interferon-y receptor immunoadhesin”, Immunology, 1993 vol. 79, pp. 594-599.

Affiliated with

Also associated with

Rating

CD95-Fc fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CD95-Fc fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD95-Fc fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2677018